
Gene Fusion Testing Market - A Global and Regional Analysis: Focus on by Category, Technology, Indication, End User, and Region - Analysis and Forecast, 2023-2033
Description
Gene Fusion Testing Market - A Global and Regional Analysis: Focus on by Category, Technology, Indication, End User, and Region - Analysis and Forecast, 2023-2033
Global Gene Fusion Testing Market Industry Overview
The global gene fusion testing market was valued at $255.3 million in 2022 and is anticipated to reach $897.6 million by 2033, witnessing a CAGR of 12.25% during the forecast period 2023-2033. The global gene fusion testing market is expected to be driven by the rising utilization of gene fusion testing in the development of targeted therapies.
Market Lifecycle Stage
The global gene fusion testing market is in progressing phase. The gene fusion testing market is experiencing rapid growth due to the rising cancer incidence because of gene fusion mutations. The demand for early detection, precise selection of targeted therapies, personalized medicine approaches, and the growing recognition and implementation of gene fusion testing in clinical settings all contribute to the escalating need for these diagnostic tests in cancer care.
Impact
Gene fusion testing is a diagnostic method that involves molecular analysis to detect and examine genetic abnormalities called gene fusions. Gene fusions arise when two distinct genes from different chromosomal locations become abnormally joined, resulting in a hybrid gene formation. This fusion can trigger the synthesis of abnormal proteins or cause changes in gene expression, potentially contributing to the development of diverse diseases, including specific types of cancer. The progression of cancer is influenced by a variety of genetic changes, encompassing mutations, deletions, gene fusions, amplifications, and rearrangements. In addition, the entry of several established players, such as Amoy Diagnostics Co., Ltd., Arima Genomics, Biocartis, Biocare Medical, LLC, Danaher Corporation, F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Illumina, Inc., Myriad Genetics, Inc., and others, is expected to aid the market growth.
Reducing the need for time-consuming and expensive laboratory assays, AI-powered prediction models can help identify patients who should receive further tests for diagnosis first. These models could identify novel, previously undetected gene fusion events, enhancing the comprehension of the genomic environment of malignancies and assisting in the design of targeted therapeutics.
Market Segmentation:
Segmentation 1: by Category
- Research
- Diagnostic
Based on category type, the research segment dominated the global gene fusion testing market in FY2022. The increasing adoption of kits, assays, and accessories contributed to the prominence of the research segment. Research use assays and kits in gene fusion testing are specifically designed and intended for use in research settings rather than for diagnostic purposes. These assays and kits are valuable tools for researchers and scientists who are studying gene fusions and their implications in various diseases, particularly cancer.
Segmentation 2: by Technology
- NGS
- FISH
- PCR
- IHC
Based on technology, the NGS segment dominated the global gene fusion testing market in FY2022. Next-generation sequencing (NGS), plays a significant role in gene fusion testing. It is a powerful and advanced technology used to analyze DNA and RNA sequences with high throughput and accuracy. In the context of gene fusion testing, NGS allows for the comprehensive examination of genes and their rearrangements, enabling the identification of fusion events between different genes.
Segmentation 3: by Indication
- Solid Tumors
- Hematological Malignancies
Based on indication, the global gene fusion testing market was dominated by the solid tumors segment in FY2022. In the field of oncology, gene fusion testing in solid tumors holds significant importance within molecular diagnostics. Its primary objective is to pinpoint particular gene fusions arising from chromosomal rearrangements or translocations within tumor cells. These gene fusions can generate abnormal fusion proteins that significantly contribute to the advancement and evolution of solid tumors.
Segmentation 4: by End User
- Pharmaceutical and Biotechnology Companies
- Hospitals and Diagnostic Laboratories
- Academic and Research Centers
Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of the global gene fusion testing market in FY2022. Pharmaceutical and biotechnology companies hold an important position in the gene fusion testing market, utilizing their expertise and resources to drive innovation and propel advancements in this rapidly evolving field. They are aware of the immense potential of gene fusion testing in revolutionizing cancer diagnostics and treatment approaches.
Segmentation 5: by Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Rest-of-the-World
Demand - Drivers and Limitations
Market Demand Drivers:
- Rising Cancer Incidence Due to Gene Fusion Mutations
- Increasing Utilization of Gene Fusion Testing in the Development of Targeted Therapies
- Global Rise in Research Grants Dedicated to Cancer Screening and Prevention Efforts
- Complexity of Testing Process
- Lack of Standardization and Reimbursement Barriers
- Increasing Demand of Gene Fusion Testing in Clinical Research
- Leveraging Artificial Intelligence to Predict Gene Fusion Status in Several Cancer Type
Workflow/Innovation Strategy: The gene fusion testing market (by indication) has been segmented into solid tumors and hematological malignancies. Moreover, the study provides the reader with a detailed understanding of the different indication of gene fusion testing in solid tumors.
Growth/Marketing Strategy: Gene fusion testing is a molecular diagnostic method employed to identify and analyze distinct genetic alterations in cancer cells. It arises when two distinct genes, typically from different chromosomes, abnormally join together, giving rise to a hybrid gene that generates a unique protein with modified functions.
Competitive Strategy: Key players in the global gene fusion testing market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the global gene fusion testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.
Key Market Players and Competition Synopsis
The gene fusion testing market encompasses the healthcare industry segment focused on developing, producing, and commercializing tests and technologies designed to detect and analyze gene fusions. Gene fusion testing involves the identification of abnormal fusion events where two separate genes join together, leading to the formation of fusion proteins with modified functions. These genetic alterations are commonly associated with various diseases, particularly cancer. In this study, several types of fundamental technologies have been examined that have facilitated these advances, namely, polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH). The global gene fusion testing market is strongly driven by the continuous introduction of advanced technologies as well as increased investments and funding from both the government and private sectors.
Key Companies Profiled:
- Amoy Diagnostics Co., Ltd.
- ArcherDX (Integerated DNA Technologies, Inc.)
- Arima Genomics
- Biocartis
- Biocare Medical, LLC
- F. Hoffmann-La Roche Ltd
- Guardant Health, Inc
- Illumina, Inc.
- Myriad Genetics, Inc.
- Natera, Inc.
- NeoGenomics, Inc.
- OncoDNA
- QIAGEN N.V.
- Quest Diagnostics Incorporated.
- Thermo Fisher Scientific Inc.
*PDF email from publisher allows for 1-3 users, with permission to print*
Table of Contents
239 Pages
- 1 Product Definition
- 1.1 Inclusion and Exclusion Criteria
- 2 Market Scope
- 2.1 Scope of the Study
- 2.2 Key Questions Answered in the Report
- 3 Research Methodology
- 4 Market Overview
- 4.1 Introduction to Gene Fusion Testing
- 4.1.1 Different Technologies for Gene Fusion Testing
- 4.1.2 Advantages and Limitations of Gene Fusion Testing
- 4.1.3 Current Market Size and Future Growth Potential, $Million, 2022-2033
- 4.1.3.1 Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion vs. Other Gene Fusions
- 4.1.4 Role of Artificial Intelligence (AI) and Machine Learning (ML) in Gene Fusion Testing
- 4.1.5 Reimbursement Landscape
- 4.2 Stakeholder’s Survey Response
- 4.2.1 Awareness of Gene Fusion Testing
- 4.2.2 Familiarity with the NGS Offerings of the Following Companies
- 4.2.3 Adoption and Barriers for Gene Fusion Testing
- 5 Industry Outlook
- 5.1 Regulatory Landscape
- 5.1.1 Legal Requirements and Frameworks in the U.S.
- 5.1.1.1 CMS Regulation (Reimbursement Scenario)
- 5.1.1.2 Marketing Authorization
- 5.1.2 Legal Requirements and Frameworks in Europe
- 5.1.3 Legal Requirements and Frameworks in Asia-Pacific
- 5.1.3.1 Legal Requirements and Framework in China
- 5.1.3.2 Legal Requirements and Framework in Japan
- 6 Global Gene Fusion Testing Market: Market Dynamics
- 6.1 Market Drivers
- 6.1.1 Rising Cancer Incidence due to Gene Fusion Mutations
- 6.1.2 Increasing Utilization of Gene Fusion Testing in the Development of Targeted Therapies
- 6.1.3 Global Rise in Research Grants Dedicated to Cancer Screening and Prevention Efforts
- 6.1.4 Impact Analysis
- 6.2 Business Restraints
- 6.2.1 Complexity of Testing Process
- 6.2.2 Lack of Standardization and Reimbursement Barriers
- 6.2.3 Impact Analysis
- 6.3 Business Opportunities
- 6.3.1 Increasing Demand for Gene Fusion Testing in Clinical Research
- 6.3.2 Leveraging Artificial Intelligence to Predict Gene Fusion Status in Several Cancer Types
- 7 Global Gene Fusion Testing Market: Competitive Insights
- 7.1 Overview
- 7.2 Key Strategies and Developments
- 7.2.1 Product Approvals and Launches
- 7.2.2 Partnerships and Collaborations
- 7.2.3 Mergers and Acquisitions
- 7.2.4 Other Developments
- 7.3 Market Share Analysis
- 7.3.1 By Company
- 7.4 Growth-Share Analysis
- 7.4.1 By Company
- 7.4.2 By Technology
- 7.4.3 By Indication
- 7.4.4 By End User
- 8 Global Gene Fusion Testing Market (by Category), Value ($Million), 2022-2033
- 8.1 Overview
- 8.2 Research
- 8.3 Diagnostic
- 9 Global Gene Fusion Testing (by Technology), Value ($Million), 2022-2033
- 9.1 Overview
- 9.2 Next-Generation Sequencing (NGS)
- 9.3 Fluorescence In-Situ Hybridization (FISH)
- 9.4 Polymerase Chain Reaction (PCR)
- 9.5 Immunohistochemistry (IHC)
- 10 Global Gene Fusion Testing Market (by Indication), Value ($Million), 2022-2033
- 10.1 Overview
- 10.2 Solid Tumors
- 10.2.1 Lung Cancer
- 10.2.2 Breast Cancer
- 10.2.3 Colorectal Cancer
- 10.2.4 Thyroid Cancer
- 10.2.5 Others
- 10.3 Hematological Malignancies
- 11 Global Gene Fusion Testing Market (by End User), Value ($Million), 2022-2033
- 11.1 Overview
- 11.2 Pharmaceutical and Biotechnology Companies
- 11.3 Hospitals and Diagnostic Laboratories
- 11.4 Research and Academic Centers
- 12 Global Gene Fusion Testing Market (by Region), Value ($Million), 2022-2033
- 12.1 Overview
- 12.2 North America
- 12.2.1 North America Gene Fusion Testing Market, by Indication
- 12.2.2 North America Gene Fusion Testing Market (by Country)
- 12.2.2.1 U.S.
- 12.2.2.1.1 U.S. Gene Fusion Testing Market (by Indication)
- 12.2.2.2 Canada
- 12.2.2.2.1 Canada Gene Fusion Testing Market (by Indication)
- 12.3 Europe
- 12.3.1 Europe Gene Fusion Testing Market, by Indication
- 12.3.2 Europe Gene Fusion Testing Market (by Country)
- 12.3.2.1 Germany
- 12.3.2.1.1 Germany Gene Fusion Testing Market (by Indication)
- 12.3.2.2 France
- 12.3.2.2.1 France Gene Fusion Testing Market (by Indication)
- 12.3.2.3 U.K.
- 12.3.2.3.1 U.K. Gene Fusion Testing Market (by Indication)
- 12.3.2.4 Italy
- 12.3.2.4.1 Italy Gene Fusion Testing Market (by Indication)
- 12.3.2.5 Spain
- 12.3.2.5.1 Spain Gene Fusion Testing Market (by Indication)
- 12.3.2.6 Netherlands
- 12.3.2.6.1 Netherlands Gene Fusion Testing Market (by Indication)
- 12.3.2.7 Rest-of-Europe
- 12.3.2.7.1 Rest-of-Europe Gene Fusion Testing Market (by Indication)
- 12.4 Asia-Pacific
- 12.4.1 Asia-Pacific Gene Fusion Testing Market, by Indication
- 12.4.2 Asia-Pacific Gene Fusion Testing Market (by Country)
- 12.4.2.1 China
- 12.4.2.1.1 China Gene Fusion Testing Market (by Indication)
- 12.4.2.2 Japan
- 12.4.2.2.1 Japan Gene Fusion Testing Market (by Indication)
- 12.4.2.3 India
- 12.4.2.3.1 India Gene Fusion Testing Market (by Indication)
- 12.4.2.4 Australia
- 12.4.2.4.1 Australia Gene Fusion Testing Market (by Indication)
- 12.4.2.5 South Korea
- 12.4.2.5.1 South Korea Gene Fusion Testing Market (by Indication)
- 12.4.2.6 Rest-of-Asia-Pacific
- 12.4.2.6.1 Rest-of-Asia-Pacific Gene Fusion Testing Market (by Indication)
- 12.5 Latin America
- 12.5.1 Latin America Gene Fusion Testing Market, by Indication
- 12.5.2 Latin America Gene Fusion Testing Market (by Country)
- 12.5.2.1 Brazil
- 12.5.2.1.1 Brazil Gene Fusion Testing Market (by Indication)
- 12.5.2.2 Mexico
- 12.5.2.2.1 Mexico Gene Fusion Testing Market (by Indication)
- 12.5.2.3 Rest-of-Latin America
- 12.5.2.3.1 Rest-of-Latin America Gene Fusion Testing Market (by Indication)
- 12.6 Rest-of-the-World
- 12.6.1 Rest-of-the-World Gene Fusion Testing Market (by Indication)
- 13 Markets - Competitive Benchmarking & Company Profiles
- 13.1 Overview
- 13.2 Amoy Diagnostics Co., Ltd.
- 13.2.1 Company Overview
- 13.2.2 Role of Amoy Diagnostics Co., Ltd. in the Global Gene Fusion Testing Market
- 13.2.3 Key Competitors
- 13.2.4 Recent Developments
- 13.2.5 Analyst Perspective
- 13.3 ArcherDX (Integerated DNA Technologies, Inc.)
- 13.3.1 Company Overview
- 13.3.2 Role of ArcherDX (Integerated DNA Technologies, Inc.) in the Global Gene Fusion Testing Market
- 13.3.3 Key Competitors
- 13.3.4 Recent Developments
- 13.3.5 Analyst Perspective
- 13.4 Arima Genomics
- 13.4.1 Company Overview
- 13.4.2 Role of Arima Genomics in the Global Gene Fusion Testing Market
- 13.4.3 Key Competitors
- 13.4.4 Recent Developments
- 13.4.5 Analyst Perspective
- 13.5 Biocartis
- 13.5.1 Company Overview
- 13.5.2 Role of Biocartis in the Global Gene Fusion Testing Market
- 13.5.3 Key Competitors
- 13.5.4 Recent Developments
- 13.5.5 Financials
- 13.5.6 Key Insights about the Financial Health of the Company
- 13.5.7 Analyst Perspective
- 13.6 Biocare Medical, LLC
- 13.6.1 Company Overview
- 13.6.2 Role of Biocare Medical, LLC in the Gene Fusion Testing Market
- 13.6.3 Key Competitors
- 13.6.4 Recent Developments
- 13.6.5 Analyst Perspective
- 13.7 F. Hoffmann-La Roche Ltd
- 13.7.1 Company Overview
- 13.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Gene Fusion Testing Market
- 13.7.3 Key Competitors
- 13.7.4 Recent Developments
- 13.7.5 Financials
- 13.7.6 Key Insights about the Financial Health of the Company
- 13.7.7 Analyst Perspective
- 13.8 Guardant Health, Inc
- 13.8.1 Company Overview
- 13.8.2 Role of Guardant Health, Inc in the Global Gene Fusion Testing Market
- 13.8.3 Key Competitors
- 13.8.4 Financials
- 13.8.5 Key Insights about the Financial Health of the Company
- 13.8.6 Analyst Perspective
- 13.9 Illumina, Inc.
- 13.9.1 Company Overview
- 13.9.2 Role of Illumina, Inc. in the Global Gene Fusion Testing Market
- 13.9.3 Key Competitors
- 13.9.4 Recent Developments
- 13.9.5 Financials
- 13.9.6 Key Insights about the Financial Health of the Company
- 13.9.7 Analyst Perspective
- 13.1 Myriad Genetics, Inc.
- 13.10.1 Company Overview
- 13.10.2 Role of Myriad Genetics, Inc. in the Global Gene Fusion Testing Market
- 13.10.3 Key Competitors
- 13.10.4 Recent Developments
- 13.10.5 Financials
- 13.10.6 Key Insights about the Financial Health of the Company
- 13.10.7 Analyst Perspective
- 13.11 Natera, Inc.
- 13.11.1 Company Overview
- 13.11.2 Role of Natera, Inc. in the Global Gene Fusion Testing Market
- 13.11.3 Key Competitors
- 13.11.4 Financials
- 13.11.5 Key Insights about the Financial Health of the Company
- 13.11.6 Analyst Perspective
- 13.12 NeoGenomics, Inc.
- 13.12.1 Company Overview
- 13.12.2 Role of NeoGenomics, Inc. in the Global Gene Fusion Testing Market
- 13.12.3 Key Competitors
- 13.12.4 Recent Developments
- 13.12.5 Financials
- 13.12.6 Key Insights about the Financial Health of the Company
- 13.12.7 Analyst Perspective
- 13.13 OncoDNA
- 13.13.1 Company Overview
- 13.13.2 Role of OncoDNA in the Gene Fusion Testing Market
- 13.13.3 Key Competitors
- 13.13.4 Recent Developments
- 13.13.5 Analyst Perspective
- 13.14 QIAGEN N.V.
- 13.14.1 Company Overview
- 13.14.2 Role of QIAGEN N.V. in the Global Gene Fusion Testing Market
- 13.14.3 Key Competitors
- 13.14.4 Recent Developments
- 13.14.5 Financials
- 13.14.6 Key Insights about the Financial Health of the Company
- 13.14.7 Analyst Perspective
- 13.15 Quest Diagnostics Incorporated.
- 13.15.1 Company Overview
- 13.15.2 Role of Quest Diagnostics Incorporated. in the Global Gene Fusion Testing Market
- 13.15.3 Key Competitors
- 13.15.4 Financials
- 13.15.5 Analyst Perspective
- 13.16 Thermo Fisher Scientific Inc.
- 13.16.1 Company Overview
- 13.16.2 Role of Thermo Fisher Scientific Inc. in the Global Gene Fusion Testing Market
- 13.16.3 Key Competitors
- 13.16.4 Recent Developments
- 13.16.5 Financials
- 13.16.6 Key Insights about the Financial Health of the Company
- 13.16.7 Analyst Perspective
- List of Figures
- Figure 1: Global Gene Fusion Testing Market, $Million, 2022-2033
- Figure 2: Global Gene Fusion Testing Market: Drivers, Restraints, and Opportunities
- Figure 3: Global Gene Fusion Testing Market (by Category), $Million, 2022-2033
- Figure 4: Global Gene Fusion Testing Market (by Technology), $Million, 2022-2033
- Figure 5: Global Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 6: Global Gene Fusion Testing Market (by Region), $Million, 2022 and 2033
- Figure 7: Global Gene Fusion Testing Market Segmentation
- Figure 8: Global Gene Fusion Testing Market: Research Methodology
- Figure 9: Primary Research Methodology
- Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 11: Top-Down Approach (Segment-Wise Analysis)
- Figure 12: Different Approaches to Study Gene Fusion
- Figure 13: Different Techniques Used in Gene Fusion Testing
- Figure 14: Global Gene Fusion Testing Market, $Million, 2022-2033
- Figure 15: Artificial Intelligence and Machine Learning in Gene Fusion Testing
- Figure 16: SOPHiA DDM RNAtarget Technology Workflow
- Figure 17: Awareness to the Concept of Gene Fusion Testing
- Figure 18: Familarity with NGS Offerings by Key Market Players for Gene Fusion Testing
- Figure 19: Perceived Importance of Key Drivers to Improve Gene Fusion Testing Adoption
- Figure 20: Agreement Level with Key Barriers to Gene Fusion Testing Adoption
- Figure 21: Steps Involved in FDA Regulation
- Figure 22: FDA Guidelines for CDx Approval
- Figure 23: Criteria for CMS Coverage/Reimbursement
- Figure 24: Steps for Obtaining Marketing Authorization
- Figure 25: Europe In Vitro Diagnostic Devices Regulation Regulatory Process
- Figure 26: Workflow for Medical Device Regulations
- Figure 27: Estimated Number of New Cancer Cases, 2020 and 2030
- Figure 28: Clinical Trials Based on Gene Fusion Testing
- Figure 29: Share of Key Developments, January 2020-July 2023
- Figure 30: Number of Product Approvals and Launches (by Company), January 2020 to July 2023
- Figure 31: Partnerships and Collaborations, January 2020-July 2023
- Figure 32: Mergers and Acquisitions, January 2020-July 2023
- Figure 33: Other Developments, January 2020-July 2023
- Figure 34: Global Fusion Testing Market, Company Share Analysis, % Share, 2022
- Figure 35: Growth-Share Analysis for Global Gene Fusion Testing Market (by Company), 2021-2022
- Figure 36: Growth-Share Analysis for Global Gene Fusion Testing Market (by Technology), 2022-2033
- Figure 37: Growth-Share Analysis for Global Gene Fusion Testing Market (by Indication), 2022-2033
- Figure 38: Growth-Share Analysis for Global Gene Fusion Testing Market (by End User), 2022-2033
- Figure 39: Global Gene Fusion Testing Market (by Category)
- Figure 40: Share of Global Gene Fusion Testing Market (by Category), $Million, 2022 and 2033
- Figure 41: Global Gene Fusion Testing Market (Research), $Million, 2022-2033
- Figure 42: Global Gene Fusion Testing Market (Diagnostic), $Million, 2022-2033
- Figure 43: Global Gene Fusion Testing Market (by Technology)
- Figure 44: Share of Global Gene Fusion Testing Market (by Technology), $Million, 2022 and 2033
- Figure 45: Global Gene Fusion Testing Market (Next-Generation Sequencing), $Million, 2022-2033
- Figure 46: Global Gene Fusion Testing Market (Fluorescence In-Situ Hybridization), $Million, 2022-2033
- Figure 47: Global Gene Fusion Testing Market (Polymerase Chain Reaction), $Million, 2022-2033
- Figure 48: Global Gene Fusion Testing Market (Immunohistochemistry), $Million, 2022-2033
- Figure 49: Global Gene Fusion Testing Market (by Indication)
- Figure 50: Share of Global Gene Fusion Testing Market (by Indication), $Million, 2022 and 2033
- Figure 51: Global Gene Fusion Testing Market (by Solid Tumors), $Million, 2022 and 2033
- Figure 52: Global Gene Fusion Testing Market (Solid Tumors), $Million, 2022-2033
- Figure 53: Global Gene Fusion Testing Market (Lung Cancer), $Million, 2022-2033
- Figure 54: Global Gene Fusion Testing Market (Breast Cancer), $Million, 2022-2033
- Figure 55: Global Gene Fusion Testing Market (Colorectal Cancer), $Million, 2022-2033
- Figure 56: Global Gene Fusion Testing Market (Thyroid Cancer), $Million, 2022-2033
- Figure 57: Global Gene Fusion Testing Market (Others), $Million, 2022-2033
- Figure 58: Global Gene Fusion Testing Market (Hematological Malignancies), $Million, 2022-2033
- Figure 59: Global Gene Fusion Testing Market (by End User)
- Figure 60: Share of Global Gene Fusion Testing Market (by End User), $Million, 2022 and 2033
- Figure 61: Global Gene Fusion Testing Market (Pharmaceutical and Biotechnology Companies), $Million, 2022-2033
- Figure 62: Global Gene Fusion Testing Market (Hospitals and Diagnostic Laboratories), $Million, 2022-2033
- Figure 63: Global Gene Fusion Testing Market (Research and Academic Centers), $Million, 2022-2033
- Figure 64: Global Gene Fusion Testing Market (by Region), $Million, 2022 and 2033
- Figure 65: North America Gene Fusion Testing Market, $Million, 2023-2033
- Figure 66: North America: Market Dynamics
- Figure 67: North America Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 68: North America Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 69: U.S. Gene Fusion Testing Market, $Million, 2022-2033
- Figure 70: U.S. Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 71: U.S. Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 72: Canada Gene Fusion Testing Market, $Million, 2022-2033
- Figure 73: Canada Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 74: Canada Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 75: Europe Gene Fusion Testing Market, $Million, 2022-2033
- Figure 76: Europe: Market Dynamics
- Figure 77: Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 78: Europe Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 79: Germany Gene Fusion Testing Market, $Million, 2022-2033
- Figure 80: Germany Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 81: Germany Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 82: France Gene Fusion Testing Market, $Million, 2022-2033
- Figure 83: France Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 84: France Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 85: U.K. Gene Fusion Testing Market, $Million, 2022-2033
- Figure 86: U.K. Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 87: U.K. Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 88: Italy Gene Fusion Testing Market, $Million, 2022-2033
- Figure 89: Italy Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 90: Italy Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 91: Spain Gene Fusion Testing Market, $Million, 2022-2033
- Figure 92: Spain Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 93: Spain Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 94: Netherlands Gene Fusion Testing Market, $Million, 2022-2033
- Figure 95: Netherlands Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 96: Netherlands Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 97: Rest-of-Europe Gene Fusion Testing Market, $Million, 2022-2033
- Figure 98: Rest-of-Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 99: Rest-of-Europe Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 100: Asia-Pacific Gene Fusion Testing Market, $Million, 2022-2033
- Figure 101: Asia-Pacific: Market Dynamics
- Figure 102: Asia-Pacific Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 103: Asia-Pacific Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 104: China Gene Fusion Testing Market, $Million, 2022-2033
- Figure 105: China Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 106: China Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 107: Japan Gene Fusion Testing Market, $Million, 2022-2033
- Figure 108: Japan Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 109: Japan Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 110: India Gene Fusion Testing Market, $Million, 2022-2033
- Figure 111: India Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 112: India Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 113: Australia Gene Fusion Testing Market, $Million, 2022-2033
- Figure 114: Australia Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 115: Australia Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 116: South Korea Gene Fusion Testing Market, $Million, 2022-2033
- Figure 117: South Korea Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 118: South Korea Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 119: Rest-of-Asia-Pacific Gene Fusion Testing Market, $Million, 2022-2033
- Figure 120: Rest-of-Asia-Pacific Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 121: Rest-of-Asia-Pacific Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 122: Latin America Gene Fusion Testing Market, $Million, 2023-2033
- Figure 123: Latin America: Market Dynamics
- Figure 124: Latin America Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 125: Latin America Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 126: Brazil Gene Fusion Testing Market, $Million, 2022-2033
- Figure 127: Brazil Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 128: Brazil Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 129: Mexico Gene Fusion Testing Market, $Million, 2022-2033
- Figure 130: Mexico Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 131: Mexico Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 132: Rest-of-Latin America Gene Fusion Testing Market, $Million, 2022-2033
- Figure 133: Rest-of-Latin America Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 134: Rest-of-Latin America Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 135: Rest-of-the-World Gene Fusion Testing Market, $Million, 2022-2033
- Figure 136: Rest-of-the-World Gene Fusion Testing Market (by Indication), $Million, 2022-2033
- Figure 137: Rest-of-the-World Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
- Figure 138: Global Gene Fusion Testing Market (by Total Number of Companies Profiled)
- Figure 139: Amoy Diagnostics Co., Ltd.: Product Portfolio
- Figure 140: ArcherDX (Integerated DNA Technologies, Inc.): Product Portfolio
- Figure 141: Arima Genomics: Product Portfolio
- Figure 142: Biocartis: Product Portfolio
- Figure 143: Biocartis: Overall Financials, $Million, 2020-2022
- Figure 144: Biocartis: Revenue (by Segment), $Million, 2020-2022
- Figure 145: Biocartis: Revenue (by Region), $Million, 2020-2022
- Figure 146: Biocartis: R&D Expenditure, $Million, 2020-2022
- Figure 147: Biocare Medical, LLC: Product Portfolio
- Figure 148: Empire Genomics, Inc.: Product Portfolio
- Figure 149: F. Hoffmann-La Roche Ltd: Product Portfolio
- Figure 150: F. Hoffmann-La Roche Ltd: Product Portfolio
- Figure 151: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
- Figure 152: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
- Figure 153: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
- Figure 154: Guardant Health, Inc: Product Portfolio
- Figure 155: Guardant Health, Inc: Overall Financials, $Million, 2020-2022
- Figure 156: Guardant Health, Inc: Revenue (by Segment), $Million, 2020-2022
- Figure 157: Guardant Health, Inc: Revenue (by Region), $Million, 2020-2022
- Figure 158: Guardant Health, Inc: R&D Expenditure, $Million, 2020-2022
- Figure 159: Illumina, Inc.: Overall Product Portfolio
- Figure 160: Illumina, Inc.: Overall Financials, $Million, 2020-2022
- Figure 161: Illumina, Inc.: Revenue (by Segment), $Million, 2020-2022
- Figure 162: Illumina, Inc.: Revenue (by Region), $Million, 2020-2022
- Figure 163: Illumina, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 164: Myriad Genetics, Inc.: Product Portfolio
- Figure 165: Myriad Genetics, Inc.: Overall Financials, $Million, 2020-2022
- Figure 166: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2020-2022
- Figure 167: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 168: Natera, Inc.: Product Portfolio
- Figure 169: Natera, Inc. Overall Financials, $Million, 2020-2022
- Figure 170: Natera, Inc.: Revenue (by Segment), $Million, 2020-2022
- Figure 171: Natera, Inc.: Revenue (by Region), $Million, 2020-2022
- Figure 172: Natera, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 173: NeoGenomics, Inc.: Product Portfolio
- Figure 174: NeoGenomics, Inc.: Overall Financials, $Million, 2020-2022
- Figure 175: NeoGenomics, Inc.: Revenue (by Segment), $Million, 2020-2022
- Figure 176: NeoGenomics, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 177: OncoDNA: Product Portfolio
- Figure 178: QIAGEN N.V.: Product Portfolio
- Figure 179: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
- Figure 180: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
- Figure 181: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
- Figure 182: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
- Figure 183: Quest Diagnostics Incorporated.: Product Portfolio
- Figure 184: Quest Diagnostics Incorporated.: Overall Financials, $Million, 2020-2022
- Figure 185: Quest Diagnostics Incorporated.: Revenue (by Segment), $Million, 2020-2022
- Figure 186: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 187: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
- Figure 188: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
- Figure 189: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
- Figure 190: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022
- List of Tables
- Table 1: Global Gene Fusion Testing Market, Impact Analysis
- Table 2: Key Questions Answered in the Report
- Table 3: Advantages of Gene Fusion Testing
- Table 4: Limitations of Gene Fusion Testing
- Table 5: NTRK Gene Fusion in Different Types of Cancer
- Table 6: Different Types of Gene Fusion
- Table 7: Gene Fusion Testing Market: Global Regulatory Scenario
- Table 8: Gene Fusion Mutations in Cancer
- Table 9: Tissue-Agnostic Targeted Therapies Approved by FDA
- Table 10: Global Grants for Cancer Screening
- Table 11: Impact Analysis: Business Drivers
- Table 12: Gene Fusion Testing Methods: Challenges
- Table 13: Impact Analysis: Business Restraints
- Table 14: Artificial Intelligence in the Field of Gene Fusion Testing
- Table 15: Companies Offering Research Use Products
- Table 16: Companies Offering Diagnostic Products
- Table 17: NTRK Test Rate Across Several Europen Countries
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.